These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35452007)

  • 1. Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
    Høilund-Carlsen PF; Werner TJ; Alavi A; Revheim ME
    Clin Nucl Med; 2022 Jul; 47(7):625-626. PubMed ID: 35452007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary: Aducanumab-Related ARIA: Paean or Lament?
    Wassef HR; Colletti PM
    Clin Nucl Med; 2022 Aug; 47(8):707-709. PubMed ID: 35543641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Aducanumab-Related ARIA: Paean or Lament?
    Wassef HR; Colletti PM
    Clin Nucl Med; 2023 Feb; 48(2):168-169. PubMed ID: 36607365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 8. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Aducanumab-Related ARIA: Paean or Lament?
    Høilund-Carlsen PF; Alavi A; Revheim ME
    Clin Nucl Med; 2023 Jun; 48(6):505-506. PubMed ID: 36724162
    [No Abstract]   [Full Text] [Related]  

  • 10. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab for the treatment of Alzheimer's disease.
    Tagliapietra M
    Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making the Case for Accelerated Withdrawal of Aducanumab.
    Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
    J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aducanumab (Aduhelm) for Alzheimer's disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258
    [No Abstract]   [Full Text] [Related]  

  • 15. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian perspective on Biogen's aducanumab trial.
    Temp AGM; Ly A; van Doorn J; Wagenmakers EJ; Tang Y; Lutz MW; Teipel S
    Alzheimers Dement; 2022 Nov; 18(11):2341-2351. PubMed ID: 35235700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we learn lessons from the FDA's approval of aducanumab?
    Liu KY; Howard R
    Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA.
    Gandy S; Knopman DS; Sano M
    Mol Neurodegener; 2021 Nov; 16(1):74. PubMed ID: 34736482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.